4 recruiting, 1 completed, 1 enrolling by invitation, 1 unknown. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Recruiting 4, Completed 1, Enrolling by invitation 1, Unknown 1, Withdrawn 1 |
Follow Staphylococcus Aureus Bacteremia: new trials by email Literature Review of Staphylococcus Aureus Bacteremia trials Research Report on Staphylococcus Aureus Bacteremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) - Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Intermountain Health Care, Inc. | 2096 | 2026-02-01 | 2026-09-25 |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA - Staphylococcus Aureus Bacteremia | Phase 4 | Enrolling by invitation | West Virginia University | 300 | 2025-09-15 | 2026-09-17 |
| Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2024-11-14 | 2026-09-09 |
| Staphylococcus Aureus Network Adaptive Platform Trial Cefazolin, Penicillin, Clindamycin - Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | University of Melbourne | 8000 | 2022-02-16 | 2026-05-06 |
| Oritavancin for Staphylococcus Aureus Infections in Opioid Users Oritavancin Injection - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 4 | Withdrawn | University of Pennsylvania | 2019-07-01 | 2022-04-06 | |
| Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia Antibiotic therapy duration for 7 days - Staphylococcus Aureus Bacteremia | Phase 4 | Unknown | Thomas Benfield | 284 | 2018-06-01 | 2020-10-19 |
| Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia Ceftaroline fosamil - Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia | Phase 4 | Completed | Forest Laboratories | 56 | 2013-01-01 | 2014-07-31 |
Bacteremia (1) · Infections (1) · Staphylococcal Infections (1)
Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Gram-Positive Bacterial Infections (1) · Infections (1) · Inflammation (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Sepsis (1) · Systemic Inflammatory Response Syndrome (1)
Daptomycin (3) · Vancomycin (3) · Cefazolin (2) · Ceftaroline (2) · Clindamycin (1) · Dabigatran (1) · Ertapenem (1) · Injections (1) · Lincomycin (1) · Nafcillin (1) · Oxacillin (1) · Penicillin G (1) · Penicillins (1) · Rifampin (1) · Rivaroxaban (1)
Forest Laboratories (1) · Intermountain Health Care, Inc. (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Thomas Benfield (1) · Todd C. Lee MD MPH FIDSA (1) · University of Melbourne (1) · University of Pennsylvania (1) · West Virginia University (1)
United States (5) · Canada (3) · Australia (2) · New Zealand (2) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · Netherlands (1) · Singapore (1) · South Africa (1) · Sweden (1) · United Kingdom (1)
Arif R Sawari, MD, MSc, MBA (1) · Brandon J Webb, MD (1) · Emily G McDonald, MD MSC (1) · Joy J Juskowich, MD (1) · Pablo Tebas, MD (1) · Prof Joshua Davies (1) · Prof Steven Tong (1) · Todd C Lee, MD MPH FIDSA (1)
PMID 39934879, PMID 41387009, PMID 41433510, PMID 42308484, PMID 42309115
2025 (2), 2017 (1)